Evidence map›Paper›PMID 25764160›Full record

ArticleInternational journal of molecular sciences2015

Helper T lymphocyte response in the peripheral blood of patients with intraepithelial neoplasia submitted to immunotherapy with pegylated interferon-α.

Márcia Antoniazi Michelin, Letícia Montes, Rosekeila Simões Nomelini, Marco Aurélio Trovó, Eddie Fernando Candido Murta

Open access · goldAbstract readControlled Clinical Trial
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Journal of experimental & clinical cancer research : CR · 2017
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Márcia Antoniazi MichelinOncology Research Institute (IPON), Federal University of the TriânguloMineiro (UFTM), Uberaba, Minas Gerais 38022-200, Brazil. michelinimuno@icbn.uftm.edu.br.
Letícia MontesOncology Research Institute (IPON), Federal University of the TriânguloMineiro (UFTM), Uberaba, Minas Gerais 38022-200, Brazil. letsmontes@yahoo.com.br.
Rosekeila Simões NomeliniDiscipline of Gynecology and Obstetrics, UFTM, Uberaba, Minas Gerais 38022-200, Brazil. rosekeila@terra.com.br.
Marco Aurélio TrovóDiscipline of Gynecology and Obstetrics, UFTM, Uberaba, Minas Gerais 38022-200, Brazil. marcotrovo@yahoo.com.br.
Eddie Fernando Candido MurtaOncology Research Institute (IPON), Federal University of the TriânguloMineiro (UFTM), Uberaba, Minas Gerais 38022-200, Brazil. eddiemurta@mednet.com.br.
Universidade Federal do Triângulo Mineiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4+) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4+ T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4+ T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4+ T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern.

Indexed as

ImmunotherapyAdolescentAdultAgedAged, 80 and overCD4-Positive T-LymphocytesFemaleHumansInterferon-alphaInterferon alpha-2Interferon-gammaInterleukinsMiddle AgedPolyethylene GlycolsRecombinant ProteinsTransforming Growth Factor betaInterferon-alphaInterferon alpha-2Interferon-gammaInterleukinspeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsTransforming Growth Factor betaTumor Necrosis Factor-alpha

Identifiers

PMID25764160
PMCPMC4394488
OpenAlexW1996709264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.